In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms
Blood · 2024
DOI: 10.1182/blood.2023022804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2024. Verfasst von Angelo B A Laranjeira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, NF-kappa B, Signal Transduction. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Hyperactivation of the NF-κB cascade propagates oncogenic signaling and proinflammation, which together augments disease burden in myeloproliferative neoplasms (MPNs). Here, we systematically ablate NF-κB signaling effectors to identify core dependencies using a series of primary samples and syngeneic and patient–derived xenograft (PDX) mouse models. Conditional knockout of Rela attenuated Jak2V617F- and MPLW515L-driven onset of polycythemia vera and myelofibrosis disease hallmarks, respectively. In PDXs, RELA knockout diminished leukemic engraftment and bone marrow fibrosis while extending survival. Knockout of upstream effector Myd88 also alleviated disease burden; conversely, perturbation of negative regulator miR-146a microRNA induced earlier lethality and exacerbated disease. Perturbation of NF-κB effectors further skewed the abundance and distribution of hematopoietic multipotent progenitors. Finally, pharmacological targeting of interleukin-1 receptor–associated kinase 4 (IRAK4) with inhibitor CA-4948 suppressed disease burden and inflammatory cytokines specifically in MPN without inducing toxicity in nondiseased models. These findings highlight vulnerabilities in MPN that are exploitable with emerging therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
- Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH.
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.
- Immunomonitoring Laboratory, Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO.
ORCID-Profile: Angelo B A Laranjeira, Tim Kong, Daniel T Starczynowski, Stephen T Oh
Förderung
- NIAMS NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Laranjeira, A. B. A., Kong, T., Snyder, S. C., Fulbright, M. C., Fisher, D. A. C., Starczynowski, D. T., & Oh, S. T. (2024). In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood. https://doi.org/10.1182/blood.2023022804
Vancouver
Laranjeira ABA, Kong T, Snyder SC, Fulbright MC, Fisher DAC, Starczynowski DT, et al. In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood. 2024. doi:10.1182/blood.2023022804
BibTeX
@article{Laranjeira2024,
author = {Laranjeira, Angelo B A and Kong, Tim and Snyder, Steven C and Fulbright, Mary C and Fisher, Daniel A C and Starczynowski, Daniel T and Oh, Stephen T},
title = {In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms},
journal = {Blood},
year = {2024},
doi = {10.1182/blood.2023022804}
}
EUVIMED